Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 3 1Phase 1 1

Status

Terminated 6Active not recruiting 4Unknown 3Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 6

Conditions

Ovarian Neoplasms 5Carcinoma, Ovarian Epithelial 3

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Terminated × oregovomab × Clear all
NCT03100006 2022-06-13

ORION-01

National Cancer Centre, Singapore

Phase 1/2 Terminated
13 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

NCT03162562 2020-12-22

The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer

CanariaBio Inc.

Phase 1 Terminated
10 enrolled
Gynecologic

Ovarian Neoplasms

NCT00034138 2007-12-18

A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma

Unither Pharmaceuticals

Phase 1/2 Terminated
24 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00034372 2007-12-18

Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma

Unither Pharmaceuticals

Phase 2 Terminated
102 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00050375 2007-12-18

Clinical Trial for Ovarian Cancer (OvaRex®)

Unither Pharmaceuticals

Phase 3 Terminated
354 enrolled
Gynecologic

Ovarian Neoplasms

NCT00086632 2007-12-18

Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment

Unither Pharmaceuticals

Phase 2 Terminated
40 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡